NXTC Sep 2024 2.500 put
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expiry date | 2024-09-20 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 53 |
GlobeNewswireNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class the
- GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today pr
- GlobeNewswire
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in com
